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Current imaging strategies 
in cardio-oncology
MIRELA TUZOVIC, MELKON HACOBIAN, AND ERIC H. YANG
INTRODUCTION
The increasing number of cancer survivors is a 
reflection of the advancements that have been 
made in early detection, and treatment with che-
motherapy, targeted therapies, immunotherapy 
and radiation (1). Cancer therapies can cause a 
range of cardiovascular adverse effects, including 
congestive heart failure, angina symptoms, acute 
coronary syndrome, stroke, arrhythmias, acceler-
ated atherosclerosis, and peripheral arterial dis-
ease (2). Structural and functional changes of the 
cardiovascular endothelium owing to chemothera-
peutic agents can lead to both short- and long-term 
sequelae that may impact long-term mortality and 
quality of life, even if the patient’s malignancy is 
successfully treated. The presence of traditional 
cardiovascular risk factors is associated with 
increased risk of developing cardiovascular com-
plications from cancer treatments. Cardiovascular 
imaging plays a crucial role in detecting both sub-
clinical changes and symptomatic disease (3,4).
Although the frequency of screening for cardio-
toxicity in patients undergoing active treatments 
and cancer survivors remains a topic of debate 
and ongoing research, screening and early diag-
nosis of cardiovascular complications of cancer 
treatments can potentially attenuate or prevent 
significant morbidity and mortality in cancer 
patients. Many different imaging modalities have 
been used for detection and monitoring of chemo-
therapeutic-related cardiotoxicity. Here, we high-
light the important advantages and disadvantages, 
as well as the specific applications of transthoracic 
echocardiography (TTE), cardiac magnetic reso-
nance imaging (CMR), multigated cardiac blood 
pool imaging (MUGA), nuclear perfusion scans, 
positron emission tomography (PET), computed 
tomography (CT), and vascular ultrasound in 
cancer patients receiving chemotherapy and/or 
radiotherapy with potential short- and long-term 
cardiovascular toxicity. We also review the car-
diotoxicity surveillance recommendations from 
the Children’s Oncology Group, International Late 
Effects of Childhood Cancer Guidelines, as well as 
five different society-endorsed statements.
IMAGING CLASSIFICATION 
OF CARDIOTOXICITY
The American Society of Echocardiography (ASE) 
and the European Association of Cardiovascular 
Imaging (EACI) define cancer therapeutic-related 
cardiac dysfunction (CTRCD) as a reduction in 
left ventricular ejection fraction (LVEF) of >10% 
to a value of <53% which should be confirmed 
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on a follow-up study in 2–3 weeks (5). Table 2.1 
lists the classifications of severity of left ventricu-
lar (LV) dysfunction, as well as the American 
College of Cardiology (ACC) and American Heart 
Association (AHA) stages of heart failure, which 
can also be applied to patients who develop cancer 
therapy-related cardiomyopathy.
While most of the guidelines on imaging for 
the detection of cardiotoxicity focus on LVEF 
assessment, other chemotherapeutic-related car-
diac effects, including radiation-induced cardiac 
disease, coronary artery thrombosis, and vaso-
spasm, will be mentioned here when appropriate. 
The cardio-oncologist now has access to a variety 
of multimodality imaging options to assess for 
cardiotoxicity, and it is critical to understand the 
strengths and weakness of each modality as well 
as the evidence to date regarding their indications 
(Table 2.2).
Transthoracic echocardiography
TTE is the most commonly used method for evalu-
ation of cardiac dysfunction from various causes. 
Echocardiography enables a comprehensive 
assessment of cardiac function, structure, valvular 
disease, and the pericardium. LVEF and right ven-
tricular (RV) function are important parameters 
to assess when CTRCD is suspected, while peri-
cardial and valve thickening are more common 
manifestations of radiation-induced cardiac dis-
ease. While chemotherapy-induced cardiotoxicity 
can affect the RV as well as the LV, changes in RV 
function is not known to be associated with worse 
outcomes. TTE also enables assessment of diastolic 
dysfunction; however, these changes have not been 
reliably predictive of cardiotoxicity (6).
TTE has tremendous advantages when com-
pared to other imaging modalities because it is 
widely available, inexpensive, portable, and is not 
associated with radiation exposure. The main limi-
tations include limited accuracy and reproducible 
measurements. LVEF measurement using 2D TTE 
biplane method (Figure 2.1) has a temporal vari-
ability/coefficient of variation of 7.4% (7), which is 
important to highlight because the measurement 
variability is close to the definition of cardiotoxic-
ity (defined as a drop in LVEF of 10% or more (5)). 
Measurement variability is the result of a number 
of factors including poor acoustic windows and 
body habitus which can affect the quality of the 
images as well as the geometric assumptions used 
to estimate 3D volumes from 2D images. Some of 
these limitations are minimized with 3D echocar-
diography measurements (Figure 2.2), which are 
not reliant on geometric assumptions. For exam-
ple, LVEF assessment with 3D echocardiography 
has a temporal variability/coefficient of variation 
of 4.0% (7). Recognizing this, the ASE encourages 
use of 3D echocardiography whenever possible (5).
Echocardiography-based deformation imag-
ing (also known as strain imaging), has become 
an essential tool for cardiotoxicity surveillance. 
While reduction in LVEF correlates with clinical 
cardiotoxicity, changes in strain are more sen-
sitive, appear prior to LVEF reduction, and are 
suggestive of subclinical cardiotoxicity. Global 
longitudinal strain (GLS) is a measure of the aver-
age change in length of the left ventricular in the 
longitudinal direction in the apical four-, three-, 
and two-chamber views. GLS has been found to be 
the best predictor of cardiotoxicity due to anthra-
cycline use (Figure 2.3). A fall in GLS between 
10% and 15% is associated with development of 
both symptomatic and asymptomatic cardiotoxic-
ity (8,9). A reduction of 15% from baseline is con-
sidered abnormal and suggestive of cardiac injury 
(10). A longitudinal strain <19% at the completion 
of anthracycline therapy has been associated with 
late development of cardiotoxicity (11). Although 
LV radial and circumferential strain are often 
measured, global radial and circumferential strain 
have not been correlated with cardiotoxicity. The 
European Society of Cardiology (ESC) and ASE 
recommend performing GLS measurements at the 
time of LVEF assessment (5,10). It is important to 
highlight that there are significant variations in 
normal strain values between vendors and track-
ing algorithms, therefore using the same software 
and vendor for follow-up studies is important (5).
Multigated cardiac blood pool 
imaging
MUGA is a nuclear-based imaging modality that uses 
a radiotracer to tag red blood cells which are counted 
as they flow through the heart allowing for an highly 
accurate assessment of cardiac function. MUGA was 
the first imaging study used for LVEF assessment 
as a way to define and track cardiotoxicity (Figure 
2.4). The initial recommendations for anthracycline-
induced cardiotoxicity monitoring were based on 
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Table 2.1 Different classification schemes for cardiac toxicity and heart failure
Classification system
Severity
Low Intermediate High
Oncology derived
 LV systolic dysfunction 
(CTCAE, version 
4.03)
– – Symptomatic as a result of 
a drop in EF; responsive 
to intervention
Refractory or poorly controlled 
HF owing to EF drop; 
intervention such as LVAD, 
vasopressor support, or heart 
transplantation indicated
Death
 Heart failure (CTCAE, 
version 4.03)
Asymptomatic with 
abnormal biomarkers or 
imaging
Symptoms with mild to 
moderate activity or 
exertion
Severe with symptoms at 
rest or with minimal 
activity or exertion; 
intervention indicated
Life-threatening consequences; 
urgent intervention indicated 
(e.g., continuous IV therapy 
or  mechanical hemodynamic 
support)
Death
 Decreased ejection 
fraction (CTCAE, 
version 4.03)
– Resting EF 40–50%; 
10–19% drop from 
baseline
Resting EF 20–39%; >20% 
drop from baseline
Resting EF <20% –
 Cardiac Review and 
Evaluation 
Committee
Any of 4 criteria confirms cardiac dysfunction: cardiomyopathy, reduced LVEF (global or more severe in the 
septum); symptoms of HF; signs associated with HF (S3 gallop and/or tachycardia); and decrease in LVEF from 
baseline ≥5% to <55% with accompanying signs or symptoms of HF or decline in LVEF ≥10% to <55% without 
accompanying signs of symptoms of HF
–
Cardiology derived
 Heart failure stage 
(ACC/AHA)
Stage A, at risk (e.g., 
patients receiving 
cardiotoxic medications 
but without structural 
heart disease or 
symptoms)
Stage B, structural heart 
disease (hypertrophy, 
low EF, valve disease)
Stage C, structural heart 
disease with prior or 
current symptoms
Stage D, refractory HF requiring 
specialized interventions
–
 NYHA symptom 
classification
Grade I, no limitations of activity
Grade II, mild limitation of 
activity; grade III, marked 
limitation of activity
Grade IV, confined to bed or 
chair
–
Source: Adapted from Khouri MG et al. Circulation. 2012;126:2749–63.
Abbreviations:  CTCAE, Common Terminology Criteria for Adverse Events; EF, ejection fraction; HF, heart failure; IV, intravenous; LVAD, left ventricular assist device; LVEF, 
left ventricular ejection fraction.
K35634_C002.indd   17
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LVEF assessment by MUGA (12). Compared to echo-
cardiography, MUGA-derived cardiac functional 
assessment is more accurate with less measurement 
variability (13); however, it does not assess valvular or 
pericardial disease, and it provides limited informa-
tion about RV function. In addition, it is both more 
costly than echocardiography and exposes the patient 
to radiation which can become significant if multiple 
follow-up studies are needed. In light of these limita-
tions and concerns, MUGA is less commonly used as 
the first-line study than echocardiography. It remains 
a good option for highly accurate LVEF assessment 
when echocardiography is suboptimal or the LVEF 
measurement is uncertain.
Cardiac magnetic resonance imaging
CMR is a newer and powerful imaging modality 
that manipulates magnetic fields to generate high 
resolution cardiac images. CMR is recognized by 
the ACC as a potential method for cardiotoxicity 
screening, and it is considered a gold standard study 
for assessment of LV function (14). CMR can assess 
both systolic and diastolic myocardial function, 
myocardial structure, and provide assessment of 
valve function. Using various sequencing methods, 
CMR can be adapted to provide virtually any infor-
mation including pericardial thickness, myocardial 
fibrosis/scar, and evidence of infiltrative disease. It 
provides tissue characterization for cardiac masses 
as well. It does not expose the patient to any radia-
tion. Compared to echocardiography, images are 
higher resolution and more reproducible; therefore, 
when discontinuation of chemotherapy is being 
considered due to cardiotoxicity, CMR should be 
used to verify the LVEF (5).
While CMR is considered a very safe test, depos-
its of gadolinium, which is the main contrast used 
in CMR, have recently been noted in the brains 
of patients undergoing multiple CMR studies. 
This has raised some concern and has prompted 
an Food and Drug Administration (FDA). Drug 
Safety warning (15). The potential effects of gado-
linium retention are currently being monitored 
and the FDA has expressed that based on current 
knowledge, the benefits of magnetic resonance 
imaging (MRI) continue to outweigh any potential 
harm. In patients with kidney dysfunction and a 
glomerular filtration rate (GFR) of less than 30 mL/
min/1.73 m2, gadolinium is contraindicated due to 
risk of a progressive condition called nephrogenic 
systemic fibrosis. Despite its breadth and accuracy, 
CMR use is limited for multiple reasons. It is expen-
sive and not available in many centers. It requires 
long exam times with significant patient coopera-
tion and long periods of breath-holding. In patients 
with pacemaker/defibrillator or breast implants, 
image quality can be limited by artifact.
CMR is well-recognized as a reliable study for 
evaluation of cardiotoxicity, and many types of 
Table 2.2 Imaging modalities currently used to evaluate cardiotoxicity
Modality Pros Cons
MUGA Reproducibility Involves radiation
Accuracy Not able to evaluate other cardiac structures
CMR Accuracy Not easily available at all centers
Can evaluate other cardiac structures Higher costs
Can evaluate myocardial perfusion, 
viability and fibrosis
TTE (2D/3D) Easy accessibility Not as accurate in evaluating LVEF when 
compared to MUGA and CMR and can miss 
small changes in LV contractility (use of 
contrast is recommended in 2D images if 
two contiguous segments are not well 
visualized in apical views)
Portability
No radiation
Can evaluate other cardiac structures 
and pulmonary hypertension
Can use speckle tracking to evaluate 
for subclinical markers like 
myocardial deformation
Abbreviations:  MUGA, multigated blood pool acquisition; CMR, cardiac magnetic resonance imaging; TTE, trans-
thoracic echocardiogram; 2D, 2-dimensional imaging; 3D, 3-dimensional imaging; LVEF, left ventricu-
lar ejection fraction.
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changes following anthracycline and trastuzumab 
treatment have been reported. Change in CMR-
derived LV mass has been shown to predict car-
diovascular events in patients with anthracycline 
cardiomyopathy (16). CMR can detect myocardial 
edema owing to acute inflammation after anthra-
cycline administration as well as an increase in 
extracellular volume which may correlate with 
myocardial fibrosis (17,18). Patients with breast 
cancer and trastuzumab-induced cardiomyopathy 
have been shown to have mid-myocardial hyper-
enhancement (19) (Figure 2.5). In contrast, late 
gadolinium enhancement (LGE), which is asso-
ciated with fibrosis/scar, is rare in anthracycline 
cardiotoxicity (16) and is largely helpful in exclud-
ing other etiologies of cardiomyopathy including 
prior myocardial infarction or amyloidosis.
Nuclear perfusion imaging
Nuclear perfusion imaging is used to assess for coro-
nary artery flow obstruction in patients with symp-
toms or signs of ischemia. It does also provide an 
assessment of LV function; however, this is not the 
test of choice for LVEF assessment due to low reli-
ability compared to echocardiography. Therefore, in 
patients with suspected cardiotoxicity—as defined 
by a change in LVEF—this test is not routinely 
Figure 2.1 Example of contrast echocardiography in a 72-year-old male with a history of metastatic 
fibrosarcoma who underwent a total cumulative dosing of 446 mg/m2 of doxorubicin, olaratumab, 
and stereotactic body radiation therapy to the right middle lung lobe for a total dose of 50 Gy, with 
anthracycline and radiation associated cardiomyopathy. The LV endocardium is opacified with injection 
of perfluten lipid microspheres (Definity, Lantheus, Billerica, MA) allowing for more accurate assessment 
of LV function and to evaluate for thrombus. Biplanar quantification of LVEF, using modified Simpson’s 
rule, was estimated at 30%. Panel (a): Apical four-chamber view in end-diastole. Panel (b): Apical four-
chamber view in end-systole. Panel (c): Apical two-chamber view in end-diastole. Panel (d): Apical two-
chamber view in end-systole. (MOD: method of disks.)
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performed. With chemotherapeutic agents associ-
ated with vascular thrombosis and vasospasm such 
as 5-flourouracil, tyrosine kinase inhibitors (TKI), 
and vascular endothelial growth factor (VEGF) 
inhibitors TKIs, perfusion imaging can be helpful 
to evaluate for cardiac ischemia in patients with 
cardiac symptoms. Screening with nuclear perfu-
sion imaging in the asymptomatic patient prior to 
or during chemotherapy has not been well studied 
and is not generally recommended. One key excep-
tion is screening for coronary artery disease (CAD) 
in patients who have received prior chest or breast 
radiation. Patients with chest and/or breast radia-
tion are at particularly high risk of CAD and have 
an estimated incidence of radiation-induced heart 
disease 5–10 years after treatment of 10%–30% (20). 
Based on one study, the prevalence of CAD based 
on coronary CT angiography in Hodgkin’s lym-
phoma survivors was up to 39% with a significant 
percentage of high risk lesions (left main or proxi-
mal left anterior descending artery) (21). The EACI 
and ASE recommend screening with a stress test 
all high-risk patients (including those who received 
anterior or left-sided chest radiation) 5–10 years 
postradiation treatment (22).
Positron emission tomography
PET is a nuclear-based imaging technique that uses 
a biologically active molecule to detect metabolic 
activity in various tissues. One important appli-
cation of PET within cardiology is for assessment 
of myocardial viability. The use of PET imaging 
for the detection of cardiotoxicity is not well stud-
ied. One small study of six female cancer patients 
undergoing doxorubicin treatment received a PET 
scan with carbon-11 acetate before and during 
chemotherapy. In this study, there was no change 
in the metabolism or blood flow associated with 
treatment (23). PET using fludeoxyglucose (a glu-
cose analog) may show changes in glucose utiliza-
tion preceding cardiotoxicity in patients receiving 
anthracyclines; however, further studies are needed 
to evaluate the significance of these changes (24).
Figure 2.2 Example of 3D volumetric transthoracic echocardiographic assessment of left ventricular 
ejection fraction. (EDV: end-diastolic volume; ESV: end systolic volume; EF: ejection fraction; SV: stroke 
volume.)
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Cardiac computed tomography
CT scanners obtain high-spatial resolution images 
providing accurate assessment of LVEF, valve 
structure, and the pericardium. CT scans are also 
able to identify the risk and presence of CAD by 
quantifying coronary calcification and visualizing 
the coronary artery lumen. Although the accuracy 
of CT is comparable to echocardiography, CT is 
not used as first line imaging for assessing cardiac 
function and structure for cardiotoxicity detec-
tion. Coronary CT angiography may have a role 
in patients who develop symptoms on particular 
chemotherapeutic agents that are linked to coro-
nary ischemia/thrombosis, such as 5-fluorouracil, 
capecitabine, paclitaxel, cisplatin, or VEGF inhibi-
tors (2–3), as cancer patients may be too high risk 
to undergo invasive coronary angiography.
An important limitation of CT that makes it less 
appealing for routine use is that it requires high 
radiation doses (22). Other limitations include 
the need for iodinated contrast, breath-holding, 
and poor image quality with elevated heart rates. 
Coronary artery and valvar disease assessment can 
Figure 2.3 Serial transthoracic echocardiographic imaging with speckle tracking of the patient from 
Figure 2.1: 72-year-old male with a history of metastatic fibrosarcoma who underwent a total cumulative 
dosing of 446 mg/m2 of doxorubicin, olaratumab, and stereotactic body radiation therapy to the right 
middle lung lobe for a total dose of 50 Gy. Panel (a): Speckle tracking in the apical four-chamber view 
3 months into treatment, demonstrating normal LVEF quantification of 68% and normal LV strain values 
in all wall segments. Longitudinal strain curves are noted below imaging. Panel (b): Representative polar 
map of study done in Panel (a), displaying peak longitudinal strain values using the two-chamber, three-
chamber, and four-chamber TTE views with a normal global longitudinal strain (GLS) value of −21.4%. 
Panel (c): Polar map of LV strain analysis performed 3 months later, showing a decrease in LV function to 
52% and a decrease in GLS value to −15.8%. Panel (d): Speckle tracking of four-chamber view of TTE 
performed 8 months after completion of doxorubicin treatment demonstrates a significant worsening 
from baseline of strain curves with an LVEF of 21%. Panel (e): Polar map of LV strain value of study done 
in Panel (d), with a GLS value of −9.5%. Panel (f): Polar map of LV strain performed on TTE study done 
5 months later on medical therapy shows a mild improvement in LVEF to 30% and mild improvement in 
GLS value of −13.3%. (Aps: apical septum; MIS: midseptum; BIS: basal septum; ApL: apical lateral; MAL: 
mid-anterolateral; BAL: basal anterolateral.)
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also be limited by the presence of calcium bloom-
ing, which can overestimate the severity of coro-
nary vessel stenosis (28).
One possible application of CT scanning is risk 
stratification in cancer patients undergoing che-
motherapy with potential cardiotoxicity. PET-CT 
scans, which are routinely performed for cancer 
staging, can also potentially provide quantitative 
coronary artery calcium burden for patients. In 
contrast to LVEF and valve assessment, CT calcium 
scores can be obtained without using high radia-
tion exposure and without contrast use. Calcium 
scores assessed on CT imaging have been shown 
to predict CAD in patients without clinical cardio-
vascular disease. The association of high coronary 
artery calcium scores has been reported in small 
studies of Hodgkin’s lymphoma and breast cancer 
survivors treated with chemoradiation (25–27). 
Patients with elevated calcium scores undergo-
ing cardiotoxic chemotherapy should undergo 
aggressive primary prevention with initiation of 
statin therapy if tolerated, as they may be at risk 
of downstream cardiac events (29). In cancer sur-
vivors who have undergone mediastinal radiation, 
cardiac CT can also provide an all-encompassing 
visualization of cardiac and vascular sequelae, 
including evaluating for radiation induced aor-
tic, pericardial, valvular, myocardial, and CAD 
(Figure 2.6).
Carotid ultrasound
Carotid duplex is a noninvasive, relatively inex-
pensive, and readily available modality to assess 
extracranial circulation that is not reliant on ion-
izing radiation. Despite advances in magnetic 
resonance angiogram and CT angiography, due 
to other limiting factors (i.e., availability, cost, 
radiation, iodinated contrast exposure, claustro-
phobia), these studies may be difficult to perform 
Figure 2.4 Example of multigated acquisition (MUGA) scan in a 32-year-old male with a history of 
presumed methamphetamine induced cardiomyopathy, diabetes, and obesity with newly diagnosed 
acute lymphoblastic leukemia undergoing anthracycline treatments. A pretreatment echocardiogram 
demonstrated suboptimal imaging, even with contrast administration, with an estimated LVEF of 36%. 
MUGA demonstrated an LVEF of 46.8%. (EF: ejection fraction; EDC: end diastolic count; ESC: end 
systolic count; TES: time to end of systole; LAO: left anterior oblique.)
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serially  (30). For asymptomatic patients with ele-
vated risk for carotid artery disease based on the 
type of cancer treatment (such as those receiving 
mediastinal and/or neck radiation), it may be rea-
sonable to obtain serial carotid ultrasounds for 
monitoring. However, in patients with signs and 
symptoms of cardiovascular disease, especially 
treated with high-risk agents such as nilotinib or 
ponatinib, carotid ultrasound and MR/CT angiog-
raphy may be considered for further identification 
Figure 2.5 Example of cardiac magnetic resonance of patient from Figure 2.1, with anthracycline and 
radiation associated cardiomyopathy. The view shown is a short axis view of the left ventricle across 
the mitral valve, with myocardial abnormal delayed enhancement of the basal to mid-interventricular 
septum (blue arrows) and basal inferolateral wall (red arrows), consistent with a nonischemic pattern. 
Invasive coronary angiography did not reveal any macrovascular disease. Left ventricular systolic 
function was severely depressed at 23%. Panel (a): Magnitude only inversion recovery (MAG) images. 
Panel (b): Phase sensitive inversion recovery (PSIR) images.
Figure 2.6 Example of cardiac computed tomography angiography (CCTA) in visualizing extent of 
chemoradiation induced cardiovascular sequelae. Multiplanar reconstructions from a pretranscatheter 
aortic valve replacement CCTA for a 57-year-old female, who had Hodgkin’s lymphoma at the age of 
16 who underwent chemotherapy and mediastinal radiation. She presented with severe aortic stenosis, 
having already had a mechanical mitral valve replacement 3 years prior. A heavily calcified (porcelain) 
aorta is seen, along with evidence of prior coronary stent placement from radiation induced CAD, along 
with severe septal calcification. (MVR: mechanical valve replacement; CAD: coronary artery disease; 
PCI: percutaneous coronary intervention.)
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of baseline, and accelerated development of athero-
sclerotic disease with treatments (2).
Measurement of carotid intima-media thickness 
(CIMT), with B-mode ultrasound is a noninvasive, 
sensitive, and reproducible technique for identify-
ing and qualifying atherosclerotic burden and car-
diovascular risk. CIMT measurements should be 
limited to the far wall of the common carotid artery, 
and should be supplemented by a thorough scan of 
the extracranial carotid arteries for the presence of 
carotid plaque, which increases the sensitivity for 
identifying subclinical vascular disease. Carotid 
plaque is defined as the presence of focal wall thick-
ening that is at least 50% greater than that of the 
surrounding vessel wall, or as a focal region with 
CIMT greater than 1.5 mm that protrudes into the 
lumen, that is distinct from the adjacent boundary. 
The presence of carotid plaque and CIMT greater 
than, or equal to 75th percentile for the patient’s 
age, sex, and race, are indicative of increased car-
diovascular risk (31). CIMT measurement has been 
used to identify patients receiving head and neck 
radiation who are at high cardiovascular risk (32) 
and may ultimately lead to more effective preven-
tion and improvement in cardiovascular outcomes.
Ankle-brachial index
Ankle-brachial index (ABI) is a simple test, which 
provides an accurate and rapid way for detecting the 
presence and severity of lower extremity arterial dis-
ease. The ABI is defined as the ratio of the systolic 
blood pressure in the upper arm compared to the 
ankle. Brachial and dorsalis pedis arterial systolic 
pressures are measured by applying an appropri-
ately sized blood pressure cuff and using a continu-
ous wave Doppler probe to record the arterial signal. 
Values below 0.9 are indicative of peripheral arte-
rial disease (30). ABI can be performed at baseline 
and annually in asymptomatic patients at risk for 
peripheral artery disease such as patients receiving 
abdominal and/or pelvic radiation. In symptomatic 
patients, especially treated with high-risk agents 
such as nilotinib or ponatinib, direct visualization 
with arterial ultrasonography or CT/MR angiogra-
phy may be indicated (2).
Venous duplex ultrasound
Deep vein thrombosis is a common problem in 
cancer patients. Compression venous ultrasound is 
considered the imaging modality of choice for the 
diagnosis of deep vein thrombosis. Using a high 
resolution linear array transducer, the deep venous 
system is usually examined from the level of the 
inguinal ligament at the common femoral vein to 
the tibioperoneal trunk. The large veins should be 
examined in the transverse plane with and without 
compression every 2–3 cm. Lack of coaptation of 
the vein wall is consistent with presence of venous 
thrombosis (30). Venous duplex should be consid-
ered in symptomatic cancer patients for detection 
of thromboembolic disease (2).
IMAGING CARDIOTOXICITY 
SURVEILLANCE GUIDELINES
A number of society-driven consensus statements 
(Table 2.3) have been published to outline cardio-
toxicity surveillance strategies based on the known 
time course of LV dysfunction with particular 
cancer treatments. Data on optimal surveillance 
continues to be limited due to the relative lack 
of long-term, wide scale studies examining the 
effects of potentially cardiotoxic treatments; also 
confounding this are the ongoing dynamic treat-
ment strategies of malignancies, and development 
of new chemotherapeutic agents with unknown 
long-term complications. Nonetheless, these state-
ments can act as a guide for short- and long-term 
cardiotoxicity surveillance and treatment of can-
cer patients and survivors.
Children’s Oncology Group
The online Children’s Oncology Group (COG) 
Long-Term Follow-Up (LTFU) Guidelines, which 
were last modified in 2018 (at the time of this 
writing), provides guidance to healthcare profes-
sionals regarding surveillance for organ toxicities 
related to chemoradiation treatments in the pedi-
atric/young adult population (33). The authors 
deemed patients at high risk for cardiotoxicity if 
they received a total cumulative dosing of doxoru-
bicin equivalent of ≥250 mg/m2 in patients. Chest 
radiation ≥35 Gy, in the absence of anthracycline 
therapy, was also considered a major risk factor 
for cardiotoxicity. The LTFU guidelines recom-
mend echocardiography as an imaging modality 
of choice with assessment of ventricular function 
at baseline, at entry into long-term follow-up, 
then periodically based on radiation dose, and 
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Table 2.3 Recommendations for surveillance for cardiac dysfunction according to major societies
Society Modality of choice Frequency of LVEF assessment
American Society of Clinical 
Oncology (ASCO)
1. Echocardiography; MUGA or MRI if 
echocardiography is not available, with MRI 
preferred over MUGA
Frequency of surveillance should be determined by the provider 
based on patient’s clinical characteristics
2. Strain imaging and biomarkers (BNP, troponin) 
could be considered in conjunction with routine 
echocardiography
Repeat assessment at 6–12 months after therapy in patients 
considered at high risk
American Society of 
Echocardiography (ASE) 
and European Association 
of Cardiovascular Imaging 
(EACVI)
1. Echocardiography, ideally incorporating 
3-dimensional imaging and global longitudinal 
strain
Baseline, end of, and 6 months after therapy associated with type I 
cardiotoxicity (i.e., anthracyclines)
2. Consider measuring high-sensitivity troponin in 
conjunction with imaging
Baseline, every 3 months during therapy associated with type II 
cardiotoxicity (ie trastuzumab)
European Society for 
Medical Oncology (ESMO)
1. Echocardiography or MUGA Baseline, every 3, 6, 9, 12, and 18 months after initiation of 
treatment
For patients with metastatic disease, obtain baseline measurement 
and only repeat if patient develops symptoms of HF
2. May consider MRI as an alternative Assessment 4 and 10 years after anthracycline therapy if treated 
<15 years of age, or >15 years with cumulative dose of 
>240 mg/m2 doxorubicin
European Society of 
Cardiology (ESC)
1. Echocardiography including 3-dimensional 
assessment of LVEF and global longitudinal strain
Baseline, every 3 months during therapy (i.e., anthracyclines or 
trastuzumab) and once after completion
2. MUGA and MRI may be considered as alterantives Repeat assessment in 2–3 weeks for any suspected cancer 
treatment related cardiac dysfunction
Canadian Cardiovascular 
Society (CCS)
1. Echocardiography including 3-dimensional imaging 
and strain, MUGA and MRI as alternatives
No specific recommendation
2. Consider concomitant measurement of biomarkers 
(BNP, troponin)
Trastuzumab Labeling 1. Echocardiography or MUGA Baseline (immediately preceding initiation of trastuzumab), every 
3 months during or upon completion of therapy, and at every 
6 months for at least 2 years following completion of therapy
Source: Adapted from Florido R et al. J Am Heart Assoc. 2017;6:e006915.
Abbreviations: MUGA, multigated acquisition; MRI, magnetic resonance imaging; BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction.
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cumulative anthracycline dose. In addition, for 
patients who have received ≥40 Gy of neck radia-
tion, carotid ultrasound is recommended 10 years 
after treatment to screen for carotid artery disease.
International Late Effects of 
Childhood Cancer Guidelines
In 2015, the International Late Effects of Child-
hood Cancer Guideline Harmonization Group 
attempted to unify different societal consensus 
statements (North American Children’s Oncology 
Group, Dutch Childhood Oncology Group, UK 
Children’s Cancer and Leukaemia Group, Scottish 
Intercollegiate Guidelines Network) owing to dis-
cordant statements ranging from cutoff doses of 
anthracyclines deemed to be high risk for develop-
ing cardiotoxicity, surveillance imaging modality 
of choice, as well as frequency of screening in the 
pediatric/young adult population (34). The total 
anthracycline cumulative dose considered high 
risk for developing cardiomyopathy was ≥250 mg/
m2 or a radiation dose of ≥35 Gy chest radiation, or 
a combination of both treatments with a moderate 
to high dose of anthracycline (≥100 mg/m2) and 
moderate to high dose chest radiation (≥15 Gy). 
Echocardiography was considered to be the sur-
veillance modality of choice for LV systolic func-
tion, but radionuclide angiography and CMR was 
also reasonable in patients where echocardiography 
was not technically feasible or optimal. For patients 
deemed low to high risk, cardiomyopathy surveil-
lance was recommended to begin no later than 2 
years after the completion of cardiotoxic therapy, 
with repeat imaging at 5 years after diagnosis and 
continued every 5 years afterwards. However, the 
authors felt that more frequent and life-long car-
diomyopathy surveillance was also reasonable for 
survivors with anthracycline exposure.
 European Society of Medical 
Oncology
Published in 2012, the European Society for Medical 
Oncology (ESMO) Clinical Practice Guidelines were 
the product of a multidisciplinary working group 
that provide guidance on cardiotoxicity surveillance, 
and a review of known cardiotoxic chemotherapeu-
tics (35). LVEF assessment with echocardiography 
was regarded as mandatory for baseline cardiac func-
tion prior to treatment with potentially cardiotoxic 
chemotherapy. They also advocated for MUGA and 
CMR as alternative imaging modalities summariz-
ing their advantages and disadvantages. For echocar-
diographic protocol, they advised image acquisition 
by 2D or 3D if available, and assessment of diastolic 
function and LV volume. At the time this document 
was written, a “high risk” cumulative dose cutoff 
of doxorubicin was >500 mg/m2, which was subse-
quently lowered in later consensus statements/guide-
lines from other societies.
For patients receiving anthracycline and/or 
trastuzumab therapy, it was advised that cardiac 
function be assessed at baseline, 3, 6, and 9 months 
during treatments, and then at 12 months and 18 
months after the initiation of treatment. The work-
ing group acknowledged that limited data were 
available for elderly patients and “increased vigi-
lance” was recommended for patients ≥60 years 
old. For patients with metastatic disease, LVEF 
should be monitored at baseline and then “infre-
quently” in the absence of symptoms. For long-
term cardiotoxicity surveillance, assessment of 
cardiac function was recommended 4 and 10 years 
after anthracycline therapy in patients who were 
treated at <15 years of age, or at age >15 years with 
a cumulative dose of doxorubicin of >240 mg/m2 
or epirubicin >360 mg/m2.
During cardiac monitoring, if an LVEF reduc-
tion of ≥15% from baseline with normal function 
(LVEF ≥50%) was noted, anthracyclines and/or 
trastuzumab could be continued. If LVEF declined 
to <50% during such treatments, the LVEF should 
be reassessed after 3 weeks. If the LVEF reduction 
was confirmed, it was advised to hold chemother-
apy and initiate cardioprotective agents with fre-
quent clinical and echocardiographic evaluation. 
If the LVEF decreased to <40%, it was advised 
that chemotherapy stop and alternatives be con-
sidered, along with initiation of treatment for LV 
dysfunction.
American Society of Clinical 
Oncology
In 2016, the American Society of Clinical Oncology 
(ASCO) published their Clinical Practice Guideline 
in the Prevention and Monitoring of Cardiac 
Dysfunction in Survivors of Adult Cancers. An 
expert panel conducted a systematic review of 104 
studies, which comprised of meta-analyses, random-
ized clinical trials, observational studies, and clinical 
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experience from 1996 to 2016 (36). This ASCO docu-
ment is notable because the threshold considered 
high risk for cardiotoxicity was lowered to a doxo-
rubicin cumulative dose of ≥250 mg/m2 or an epiru-
bicin cumulative dose of ≥600 mg/m2. In addition, 
high-dose radiotherapy (RT) with a total dose of ≥30 
Gy where the heart is in the treatment field, or a com-
bination of anthracycline and chest RT at any dose 
was considered high risk for cardiotoxicity as well.
Echocardiography is the preferred diagnostic 
imaging modality for workup of cardiac dysfunc-
tion. CMR and MUGA can be considered if echo-
cardiography is not available or technically feasible, 
with preference given to CMR. Although there are 
no specific recommendations of frequency of car-
diovascular imaging during treatments, it was rec-
ommended that an echocardiogram be performed 
between 6 and 12 months after completion of 
cancer-directed therapy in asymptomatic patients 
considered to be at increased risk of cardiotoxicity.
Canadian Cardiovascular Society
In their 2016 society guidelines, the Canadian 
Cardiovascular Society (CCS) recommended 
that patients who received potentially cardiotoxic 
cancer therapy undergo LVEF assessment before 
initiation of treatments (37). The same imag-
ing modality should be used to determine LVEF 
before, during, and after completion of therapy. 
For those undergoing echocardiographic imaging, 
myocardial strain imaging be considered as a tool 
to assist in detecting subclinical cardiotoxicity. 
They determined that a relative percentage reduc-
tion in GLS of <8% was likely not clinically sig-
nificant, whereas a relative reduction of >15% was 
likely to be abnormal. The CCS also preferred the 
use of 3D echocardiography whenever feasible and 
technically satisfactory (37). The intervals of imag-
ing were not specified in this document.
European Society of Cardiology
The ESC published an ESC Position Paper on can-
cer treatments and cardiovascular toxicity in 2016. 
The ESC Task Force determined echocardiogra-
phy to be the method of choice in the detection 
of myocardial dysfunction before, during, and 
after cancer therapy (10). They advocated for 3D 
echocardiography if endocardial definition was 
optimal, and for performing 2D biplane Simpson 
method if 3D imaging was not available or was 
suboptimal.
The task force determined that any significant 
decrease in LVEF (>10%) to a value that does not 
drop below the lower limit of normal (defined as 
an LVEF of 50%), should undergo repeated LVEF 
assessment shortly after and over the duration 
of cancer treatment. If LVEF decreases >10% to 
a value below the lower limit of normal, medical 
treatment should be initiated. The ESC also rec-
ommended considering an LVEF assessment at 
baseline, every 3 months during treatment, and 
at the end of treatment with either anthracyclines 
or trastuzumab. While they supported long-term 
surveillance after cancer treatment, no specific fre-
quency was recommended.
 American Society of 
Echocardiography/European 
Association of Cardiovascular Imaging
The ASE and European Association of Cardio-
vascular Imaging (EACVI) released a joint expert 
consensus statement in 2014, providing a proposed 
cardio-oncology echocardiography protocol (Table 
2.4), and cardiotoxicity surveillance intervals based 
on the types of chemotherapeutic agents being used 
(5). The classifications of CTRCD were divided into 
“Type I” (associated with anthracycline use and 
permanent/irreversible myocardial damage if not 
treated) and “Type II” CTRCD (associated with 
trastuzumab and tyrosine kinase inhibitors, which 
is more reversible with discontinuation of therapy 
and/or initiation of treatment). Although this clas-
sification system is oversimplified and may not be 
applicable to a variety of other novel cancer treat-
ments (i.e., targeted therapies, immunotherapy), the 
document focuses on more commonly used treat-
ments with known cardiotoxic profiles. Further 
research efforts are needed to document short- and 
long-term cardiovascular outcomes for current and 
future cancer therapy agents in order to provide a 
more nuanced, accurate classification system for 
physicians to provide adequate imaging surveillance 
for cancer patients during and after their treatments.
For patients undergoing treatments associated 
with potential irreversible (Type I) cardiotoxicity, 
it is advised to obtain an LVEF assessment at base-
line, at the end of treatment, and 6 months later 
for doxorubicin equivalent doses of <240 mg/m2, 
along with serial biomarker assessments. For doses 
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that exceed 240 mg/m2, LVEF assessment is advised 
prior to each additional 50 mg/m2. In addition, the 
ASE/EACVI consensus statement prefers that 3D 
echocardiography be used for LVEF assessment; 
however, if this is not feasible, contrast echocardiog-
raphy with GLS and troponin-I assessment can be 
considered. Cardiology consultation is advised for 
a reduction in LVEF to <53%, abnormal GLS value, 
and/or elevation in troponin levels. If abnormal 
LVEF values are seen during surveillance, CMR was 
advised for confirmation of LV dysfunction.
For patients who are receiving cancer treatments 
with potentially reversible (Type II) cardiotoxic-
ity, such as trastuzumab, or following treatment 
associated with potentially irreversible cardiotox-
icity, LVEF/GLS/troponin-I assessment is advised 
at baseline and every 3 months until treatment is 
finished. Long-term surveillance is not advised. As 
with the CCS guidelines, a GLS relative percentage 
decrease of <8% was unlikely to be clinically sig-
nificant, where as a relative percentage decrease of 
>15% was concerning for subclinical cardiotoxicity.
Although the document now advocates for 
echocardiography as the first line imaging modal-
ity of choice for cardiotoxicity surveillance, it also 
does mention historical proposed surveillance 
intervals for anthracycline induced cardiotoxicity 
with MUGA imaging (12):
 1. LVEF >50% at baseline
 a. Measurement at 250–300 mg/m2
 b. Measurement at 450 mg/m2
 c. Measurement before each dose above 
450 mg/m2
 d. Discontinue therapy if LVEF decreases by 
≥10% from baseline and LVEF ≤50%
Table 2.4 ASE/EACVI recommended cardio-oncology echocardiogram protocol
• Standard transthoracic echocardiography
• In accordance with ASE/EAE guidelines and IAC-Echo
• 2D strain imaging acquisition
• Apical three-, four-, and two-chamber views
• Acquire ≥3 cardiac cycles
• Images obtained simultaneously maintaining the same 2D frame rate and imaging depth
– Frame rate between 40 and 90 frames/sec or ≥40% of HR
• Aortic VTI (aortic ejection time)
• 2D strain imaging analysis
• Quantify segmental and global strain (GLS)
• Display the segmental strain curves from apical views in a quad format
• Display the global strain in a bull’s-eye plot
• 2D strain imaging pitfalls
• Ectopy
• Breathing translation
• 3D imaging acquisition
• Apical four-chamber full volume to assess LV volumes and LVEF calculation
• Single and multiple beats optimizing spatial and temporal resolution
• Reporting
• Timing of echocardiography with respect to the IV infusion (number of days before or after)
• Vital signs (BP, HR)
• 3D LVEF/2D biplane Simpson’s method
• GLS (echocardiography machine, software, and version used)
• In the absence of GLS, measurement of medial and lateral s’ and MAPSE
• RV: TAPSE, s’, FAC
Source: Adapted from Plana JC et al. J Am Soc Echocardiogr. 2014;27:911–39.
Abbreviations: ASE/EACVI, American Society of Echocardiography/European Association of Cardiovascular Imaging; 
BP, blood pressure; FAC, fractional area change; HR, heart rate; IAC-Echo, Intersocietal Accreditation 
Commission Echocardiography; MAPSE, mitral annular plane systolic excursion; TAPSE, tricuspid annular 
plane systolic excursion; RV, right ventricle; VTI, velocity-time integral.
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 2. LVEF <50% at baseline
 a. Do not treat if LVEF is <30%
 b. Serial measurement before each dose
 c. Discontinue therapy if LVEF decreases by 
≥10% from baseline or LVEF ≤30%
The document does not give recommendations 
for long term surveillance in cancer survivors.
In a separate document for patients undergoing 
radiotherapy, the ASE/EACVI Expert Consensus 
for Multi-Modality Imaging Evaluation of 
Cardiovascular Complications of Radiotherapy in 
Adults was released in 2013 (22). Patients at high 
risk for developing radiation-induced heart disease 
(RIHD) included the following risk factors:
 ● Anterior or left chest irradiation location, with 
one or more of the following risk factors:
 ● High cumulative dose of radiation (>30 Gy)
 ● Younger patients (<50 years)
 ● High dose of radiation fractions (>2 Gy/ day)
 ● Presence and extent of tumor in or next of 
the heart
 ● Lack of shielding
 ● Concomitant chemotherapy (i.e., anthracy-
clines cause considerably higher risk)
 ● Cardiovascular risk factors (i.e., diabe-
tes mellitus, smoking, obesity, moderate 
hypertension, hypercholesteremia)
 ● Preexisting cardiovascular disease.
Because of the complex and extensive effects of 
chest radiation exposure, including macro- and 
microvascular injury, valvular dysfunction, pro-
gressive myocardial fibrosis, and pericardial dis-
ease (38), the document discusses the indications 
of multiple imaging modalities, including echo-
cardiography, CMR, cardiac computed tomog-
raphy angiography (CTA), and functional stress 
testing for specific disease states related to RIHD. 
However, the frequency and imaging modality of 
choice in screening for subclinical/clinical RIHD 
is overall unclear; owing to the relative paucity of 
evidence, the authors recommend yearly targeted 
clinical history and physical exam of patients who 
have received chest radiation exposure. For asymp-
tomatic patients, it was reasonable to perform 
screening echocardiography to evaluate for over-
all manifestations of RIHD 5 years after exposure 
in high-risk patients, and 10 years after exposure 
in other patients. In high-risk patients, functional 
noninvasive stress testing for CAD detection 5–10 
years after exposure was reasonable, with reassess-
ment every 5 years.
For other cardiovascular manifestations, 
including valvular disease, if a cardiac murmur 
is heard, then echocardiography is indicated with 
serial imaging as per cardiology guidelines; if neu-
rological symptoms are noted, then carotid ultra-
sonography is indicated, although frequency of 
surveillance and when to initiate it for these spe-
cific disease states are not known. For suspected 
pericardial constriction from radiation, CMR was 
indicated. Workup for suspected angina/ischemia 
include echocardiography and functional nonin-
vasive stress testing, or invasive testing depending 
on clinical assessment.
American Society of Nuclear 
Cardiology
In 2016, the American Society of Nuclear 
Cardiology (ASNC) published an informa-
tion statement reviewing the cardiotoxic effects 
of cancer treatments and a review specifically 
focused on applications of nuclear cardiol-
ogy technologies (39). The statement refers to a 
variety of prior guidelines, including the ESMO 
Clinical Practice Guidelines and the COG Long 
Term Follow-Up Guidelines as previously dis-
cussed in recommendations on LVEF assessment 
during and after cancer treatment both in chil-
dren and adults.
Society of Cardiovascular 
Angiography and Interventions
In 2016, the Society of Cardiovascular Angiography 
and Interventions (SCAI) released an expert con-
sensus statement, which provided recommen-
dations on pharmacologic and interventional 
management of cancer patients with cardiotoxic-
ity, and/or preexisting or acquired atherosclerotic 
cardiovascular disease (ASCVD) (2). In addition, 
it also gave expert opinion recommendations 
on patients receiving specific kinds of radiation 
therapy that may affect the extracardiac vascula-
ture. Although data on long-term event rates are 
limited, ABIs and carotid ultrasonography was 
advised—every 5 years for the latter posttreat-
ment—particularly in patients at elevated ASCVD 
risk and who received radiation therapy to the 
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neck area (i.e., lymphoma, head and neck cancers). 
Chemotherapy agents such as cisplatin, nilotinib, 
and ponatinib were considered to be high risk 
agents for arterial/venous thrombotic disease. The 
SCAI document advises consideration of nonin-
vasive imaging modalities such as carotid ultra-
sound, as well as MRI for cerebrovascular disease 
and CT aortography for peripheral arterial disease 
assessment in patients who received agents such as 
nilotinib and ponatinib.
Similar to the ASE/EACVI expert consensus 
statements, SCAI recommends that patients who 
received RT undergo screening echocardiography 
every 5 years for high-risk patients, and every 10 
years for patients with no RIHD risk factors. The 
document also advocated for consideration of car-
diac CT angiography as an alternative to functional 
exercise stress testing every 5 years after RT, or an 
additional early evaluation at 2 years if RT was per-
formed at >60 years of age, if the patient had known 
CAD, or had one or more cardiovascular risk factors.
CONCLUSIONS
There have been many technological advances 
made in the field of echocardiography, includ-
ing the advent of 3D imaging, and strain imaging 
which has allowed for more precise LVEF assess-
ment and less dependence on imaging modalities 
that required radiation exposure (i.e., MUGA). 
Echocardiography has largely supplanted MUGA 
as the test of choice in cardiotoxicity surveil-
lance owing to improvements in imaging quality, 
as well as being able to provide information on 
chamber size, valvular function, and the pres-
ence of pericardial disease without exposing 
the patient to ionizing radiation. CMR has now 
allowed for superior imaging with visualization 
of pericardial and valvular disease, and there 
is ongoing interest in developing techniques to 
assess for subclinical/clinical cardiotoxicity with 
patterns of gadolinium enhancement in the myo-
cardium. Other advanced imaging modalities, 
such as cardiac CT angiography, may be useful 
in selected patients for assessment of athero-
sclerotic disease but have limited utility in this 
population. Arterial/venous ultrasounds remain 
useful in detecting thrombotic complications of 
cancer and their treatments, as well as sequelae 
of chemoradiation. However, the frequency and 
duration of clinical utilization, as well as cost 
effectiveness of these imaging modalities, contin-
ues to remain a question and an area of ongoing 
research and interest. Further investigations are 
warranted in refining the definition of cardio-
toxicity, and determining the ideal duration and 
method of surveillance with the armamentarium 
of advanced imaging modalities that are avail-
able—which will continue to evolve (40).
As cancer treatments continue to develop at a 
rapid pace, resulting in growing cancer survival 
rates, precise imaging modalities are critical in 
detecting preexisting and acquired cardiovascular 
disease with treatments. It is essential that cardio-
oncologists be cognizant of the dynamic nature of 
multimodality imaging and society-endorsed car-
diotoxicity surveillance recommendations for this 
unique population. In doing so, we can provide 
the most evidence-based care to cancer patients, 
ideally enable the continuation of critical cancer 
treatments, and prevent and/or minimize cardio-
vascular toxicity in the growing cancer survivor 
population.
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